Loading organizations...
Keyron develops advanced medical devices, featuring ForePass®, a non-invasive and fully reversible gastric bypass procedure. This device requires no incisions, targeting severe metabolic diseases such as Class II and III obesity, Type 2 diabetes, MASH, and hepatic fibrosis. ForePass® aims to replicate metabolic benefits of surgical interventions through a less invasive method.
Established in 2016 by CEO Giorgio Castagneto Gissey and a bariatric surgeon co-founder, Keyron addresses a critical unmet need. Many patients with severe obesity and diabetes avoid invasive surgery or find pharmaceuticals insufficient. The founders sought to bridge this gap, creating an effective, minimally invasive solution combining surgical efficacy.
Keyron serves patients with severe obesity and comorbidities like type 2 diabetes and NASH, offering alternatives to traditional surgery. The company envisions establishing new standards in severe diabesity treatment, providing a safe, effective, and entirely endoscopic procedure. Keyron strives to deliver substantial weight loss and disease reversal, redefining long-term care.
Keyron has raised $3.0M across 2 funding rounds.
Keyron has raised $3.0M in total across 2 funding rounds.
Keyron Limited is a London-based medical technology company founded in 2016 that develops innovative, non-invasive medical devices for treating metabolic diseases, including obesity (Class II & III, BMI ≥35), type 2 diabetes, NASH (non-alcoholic steatohepatitis), and liver fibrosis.[1][2][4] Its flagship product, ForePass, is the world's first fully reversible, perforation-free gastric bypass device—a Class III implantable medical device delivered endoscopically without incisions or sutures, combining a gastric balloon and intestinal sleeve to mimic metabolic surgery's effects, enabling substantial weight loss (targeting 30%+), diabetes reversal, and NASH improvement for ~55 million patients in the US and EU5 who reject surgery (99% refusal rate) or fail/quit drugs (92% fail 15% loss; 85% quit).[2][3][4] Keyron serves patients with severe "diabesity" (obesity + diabetes/comorbidities), addressing a gap where surgery is invasive and drugs underperform, with preclinical trials showing safety in swine and efficacy (diabetes/NASH reversal) in rodents; the company has raised funding from investors like Health Wildcatters (2024 cohort) and operates with <25 employees and revenue under $5M.[1][2][3]
Keyron was founded in 2016 in London, UK (headquartered at 57a Epirus Road, Fulham), by a team of globally renowned experts in diabesity, endoscopy, metabolic surgery, medical device engineering, and business leaders with track records in obesity/medtech exits.[1][2][4] Key team members include Giorgio Castagneto-Gissey, a Research Associate in Energy Economics at University College London (UCL) and employee at Keyron.[1] The idea for ForePass emerged from identifying the unmet need in severe diabesity treatment—where 99% refuse surgery despite needing 30%+ weight loss, and drugs fail most—leading to the invention of a non-surgical alternative that replicates gastric bypass via endoscopic delivery.[3][4] Early traction includes patented technology proven safe/effective in preclinical animal trials (diabetes/NASH reversal in rodents, safety in swine), participation in Health Wildcatters 2024 accelerator, and additional undisclosed investors, positioning it as a platform for replicating multiple bariatric surgeries.[1][3][4]
Keyron stands out in medtech through ForePass's engineering and clinical advantages:
Keyron rides the explosive metabolic disease medtech wave, fueled by surging obesity/diabetes epidemics (55M US/EU5 severe cases; 360-400M worldwide potential), limitations of GLP-1 drugs (high dropout, modest loss), and demand for surgery alternatives amid ~99% refusal rates.[2][3][4] Timing is ideal post-2020s GLP-1 boom (e.g., Ozempic/Wegovy), as drugs leave ~46M patients underserved, creating space for durable, reversible devices like ForePass that match surgery outcomes without invasiveness.[4] Market forces favoring Keyron include aging populations, rising NASH/liver fibrosis, regulatory push for cost-effective Class III devices, and investor interest in healthtech (e.g., Health Wildcatters backing).[1][2] It influences the ecosystem by pioneering "next-gen metabolic platforms," potentially resetting standards for endoscopy-based treatments and bridging pharma/surgery gaps.
Keyron is poised to disrupt diabesity care with ForePass advancing to human trials, leveraging preclinical wins and expert backing to capture a massive underserved market beyond drugs/surgery.[3][4] Next steps likely include clinical validation, FDA/EU approvals, partnerships with endosurgeons/hospitals, and scaling as a bariatric platform—watch for 2026+ trial data amid GLP-1 fatigue.[2][4] Trends like AI-optimized devices, personalized metabolic therapies, and global obesity surges will amplify its trajectory, evolving Keyron from innovator to category leader in non-invasive medtech, unlocking life-changing solutions for millions where current options fall short.[1][3]
Keyron has raised $3.0M in total across 2 funding rounds.
Keyron's investors include Health Wildcatters, LIFTT.
Keyron has raised $3.0M across 2 funding rounds. Most recently, it raised $30K Seed in September 2024.
